![](https://news.europawire.eu/wp-content/uploads/2023/12/Cancer-Treatment-Advances-FDA-Recognizes-Breakthrough-Potential-of-BNT323-DB-1303-for-Endometrial-Cancer-144x144.jpg)
(IN BRIEF) BioNTech and Duality Biologics have received Breakthrough Therapy designation from the FDA for their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303. The designation is for the treatment of advanced endometrial cancer in patients who have progressed following immune checkpoint inhibitor … Read the full press release